Clinical Trials Directory

Trials / Completed

CompletedNCT03310281

Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)

A Randomized, Double-blind, Controlled, 6-week Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
84 (actual)
Sponsor
Akili Interactive Labs, Inc. · Industry
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.

Detailed description

The study will be a randomized, parallel group, controlled trial of two videogame-like (iPad-based) digital therapies. The study will consist of 3 primary phases: Pre-screening, Baseline, and Treatment. During the Pre-screening Phase (Day -28 to Day 0), participants will undergo pre-screening to evaluate eligibility for the study. Pre-screening may take place up to 28 days before the Baseline Visit (Day 0). Pre-screening may take place either over the phone, or in the clinic. On Day 0, the Baseline visit will occur wherein additional eligibility criteria will be established. The Treatment Phase (Day 1 to Day 42) will involve using the digital therapy at home for each participant followed by an In-Clinic assessment on Day 42 to assess key outcomes. During the Treatment Phase participants will be instructed to play their videogame-like intervention for approximately 25 minutes per day for 5 days per week. Compliance with treatment/use requirements will be monitored remotely during this phase.

Conditions

Interventions

TypeNameDescription
DEVICEHOLD: VideogameVideogame-like digital therapy

Timeline

Start date
2017-12-04
Primary completion
2018-11-14
Completion
2018-11-14
First posted
2017-10-16
Last updated
2018-11-21

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03310281. Inclusion in this directory is not an endorsement.